Normosang (Human Hemin)

Human Hemin, the active ingredient in Normosang, is a heme (hemin) therapy presented as a lyophilized powder for solution for injection for intravenous use. It is employed to treat acute attacks of acute intermittent porphyria, hereditary coproporphyria and variegate porphyria in affected patients.

GNH USA supplies Normosang as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology units and specialty clinics worldwide, with established cold‑chain logistics and regulatory support. The company ensures product integrity through validated storage conditions and comprehensive documentation for global distribution.

Normosang (human hemin) is indicated for the management of acute porphyria attacks, acting on the heme biosynthetic pathway to suppress excess precursor accumulation.

- Acute intermittent porphyria: reduces neurotoxic porphyrin precursor buildup, alleviating abdominal pain, neuropathy and psychiatric manifestations during attacks. - Hereditary coproporphyria: supplies exogenous heme to inhibit aminolevulinic acid synthase, helping control acute neurovisceral symptoms. - Variegate porphyria: provides heme feedback inhibition to interrupt the overproduction of toxic intermediates, facilitating rapid symptom resolution.

Administration of Normosang may be associated with several adverse reactions, ranging from mild to severe.

Common Side Effects: - Infusion site pain - Nausea - Headache

Serious or Rare Side Effects: - Anaphylactic reaction - Hemolysis - Acute renal failure

Prior to using Normosang, several precautions should be observed to minimize risk and ensure safe administration.

- Monitor liver function: assess hepatic enzymes before and during therapy. - Monitor renal function: evaluate serum creatinine and urine output regularly. - Assess for hypersensitivity: discontinue infusion if signs of allergic reaction appear. - Ensure adequate hydration: maintain intravenous fluids to reduce renal complications. - Adjust use in hepatic impairment: consider dose modification under specialist guidance. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Normosang can interact with other medicines that affect the heme pathway or hepatic metabolism.

Major Interactions (Avoid): - Barbiturates (e.g., phenobarbital): induce ALAS and may worsen porphyria. - Certain anticonvulsants (e.g., phenytoin, carbamazepine): increase porphyrin precursor synthesis. - Alcohol: can precipitate acute attacks and interfere with heme metabolism.

Moderate Interactions (Monitor Closely): - Oral contraceptives: may exacerbate porphyria symptoms; monitor closely. - Iron supplements: excess iron can affect heme synthesis; observe iron status.